Immunodeficiencies and autoimmune diseases

1
Immunodeficiencies andautoimmune diseases

• Martin Liška

2
Immunodeficiencies

• Humoral innate immunity - complement, MBL
• acquired immunity
  immunoglobulins (B lymphocytes)
• Cell mediated immunity innate immunity
  phagocytes
• 
  - acquired immunity T lymphocytes
• Primary congenital, genetically defined,
  symptoms predominantly
• at early age
• Secondary the onset of symptoms at any age
• chronic diseases
• effect of
  irradiation
• immunosuppression
• surgical
  intervention, injuries
• stress

3
Immunodeficiencies critical life periods in
respect to symptoms onset

• Newborn age - severe primary disorders of cell
  mediated immunity
• 6 mth. 2 yrs. severe humoral
  immunodeficiencies
• cong./transient
• 3 - 5 yrs. transient and selective humoral
  immunodeficiencies,
• secondary
  immunodeficiencies
• 15 20 yrs. hormonal instability, thymus
  involution, life-style changes,
• some typical
  infections
• first symptoms of
  CVID
• Middleage often excessive workload, stress
• first symptoms of
  autoimmune disorders (also immunodeficiency)
• Advanced and old age rather symptoms of severe
  secondary immunodeficiencies,
  
• 
  repercussion of functional disorders

4
Immunodeficiencies major clinical features

• Antibodies - microbial infections (encapsulated
  bacteria)
• respiratory -
  pneumonia, sinusitis, otitis
  
• GIT diarrhea
• Complement system microbial infections
  (pyogenic), sepsis
• 
  edema (HAE) C1-INH deficiency
• T lymphocytes - bacterial, fungal, viral
• GIT diarrhoea
• respiratory
  pneumonia, sinusitis
• Phagocytes - abscesses, recurrent purulent skin
  infections
• granulomatous
  inflammation

5
I. Primary immunodeficiencies phagocytic cell
defects

• 1/ Quantitative decreased numbers of
  granulocytes neutrophil elastase mutation
• Congenital chronic agranulocytosis
• Cyclic agranulocytosis (neutropenia)

6
I. Primary immunodeficiencies phagocytic cell
defects

• 2/ Qualitative phagocytes functional disorders,
  various enzyme deficits, inability of phagocytes
  to degrade the ingested material
• a/ Chronic Granulomatous Disease (CGD)
• Approximately in 60 X-linked
• Enzymatic inability to generate toxic oxygen
  metabolites (H2O2) during oxygen consumption) -
  result of defect in neutrophilic cytochrome b
  (part of complex containing NADPH oxidase)
• Inability to kill bacteria such as Staph.aureus,
  Pseud.aeruginosa that produce catalase
• Clinical features granulomas of skin, organs
• Treatment long-term ATB administration

7
II. Primary immunodeficiencies B cell disorders

• Brutons X-linked hypogamaglobulinemia
• Blockage of the maturation of pre-B lymphocytes
  into B lymphocytes (tyrosine kinase defect)
• Undetectable or very low serum levels of Ig
• Pneumonia, pyogenic otitis, complicated
  sinusitis, increased occurrence of pulmonary
  fibrosis
• Treatment life-long IVIG substitution
• CVID Common Variable ImmunoDeficiency
• B cell functional disorder, mostly low levels of
  IgG and IgA
• Symptoms onset between 2nd and 3rd decade
• Recurrent respiratory tract infections
  (pneumonia)
• Treatment IVIG substitution

8
II. Primary immunodeficiencies B cell disorders

• Selective IgA deficiency
• Disorder of B cell function
• Recurrent mild/moderate infections (respiratory,
  GIT, urinary tract) or asymptomatic
• Risk of reaction to live attenuated vaccines or
  generation of anti-IgA antibodies after a blood
  transfusion
• Selective IgG subclasses or specific IgG
  deficiency
• B cell function disorder
• Onset of symptoms in childhood, mostly
  respiratory tract infections caused by
  encapsulated bacteria (H.influenzae, Pneumococci)
• Transient hypogammaglobulinemia of infancy

9
III. Primary immunodeficiencies T cell
disorders

• diGeorge syndrome
• Disorder of prethymocytes maturation due to
  absence of thymus (disorder of development of 3rd
  and 4th branchial pouch)
• Congenital heart diseases
• The onset of symptoms after the birth
  hypocalcemic spasms and manifestations of
  cong.heart disease
• Immunodeficiency could be only mild, the numbers
  of T lymphocytes later usually become normal
• Treatment symptomatic

10
IV. Primary immunodeficiencies combined
defects of T and B cells

• SCID Severe Combined ImmunoDeficiency
• X-linked recessive or AR disease, combined
  disorder of humoral and cell mediated immunity
• Severe disorder (patients often die during first
  2 years of life), onset of symptoms soon after
  birth (severe diarrhoea, pneumonia, meningitis,
  BCGitis)
• Immunological features typically lymphopenia and
  thymus hypoplasia
• Forms AR form often enzymatic deficiency (ADA,
  PNP) that leads to accumulation
• of metabolites
  toxic to DNA synthesis (lymphocytes)
• X-linked form disorder of
  stem-cell
• Treatment ATB, IVIG
• BMT is of critical
  significance
• gene therapy

11
V. Primary immunodeficiencies complement
system disorders

• Hereditary angioedema (HAE)
• Absence or functional deficiency of C1-inhibitor
• Anaphylactoid reactions with skin and/or mucosal
  (oral, laryngeal, gut) edemas caused by
  activation of kinin system
• Injuries or surgical/stomatological interventions
  are mostly triggering factor
• Laryngeal edemas could be life-threatening,
  immediate treatment is necessary !
• Treatment preventive androgens, EACA
• immediate C1-INH
  concentrate or fresh frozen plasma
• 
  administration
• -
  newly bradykinin receptor antagonist (icatibant)
  

12
Secondary immunodeficiencies

• Acute and chronic viral infections infectious
  mononucleosis, influenza
• Metabolic disorders diabetes mellitus, uremia
• Autoimmune diseases autoantibodies against
  immunocompetent cells (neutrophils, lymphocytes)
  autoimmune phenomena also after administration of
  certain drugs (e.g. oxacilin, quinidine)
• Chronic GIT diseases
• Malignant diseases (leukemia)
• Hypersplenism/asplenia
• Burn, postoperative status, injuries
• Severe nutritional disorders
• Chronic infections
• Ionizing radiation
• Drug induced immunodeficiencies (chemotherapy)
• Immunosupressive therapy
• Chronic stress
• Chronic exposure to harmful chemical substances

13
Secondary immunodeficiencies - A.I.D.S.

• Caused by retrovirus HIV 1 or HIV 2
• Virus has a tropism for cells bearing CD4 surface
  marker (Th CD4 lymphocytes) also affects
  macrophages and CNS cells
• Viral genome transcribes into human DNA and
  infected cell provides viral replication
• Transmission sexual intercourse
• contact with blood
• endouterine
  (mother fetus, breast milk)
• Phases acute (flu-like sy)
• asymptomatic several
  years, viral replication
• symptomatic infections,
  autoimmune disorders, malignancy,
  
• 
  allergy
• final systemic breakdown,
  opportune infections

14
A.I.D.S. - Treatment

• Reverse transcriptase inhibitors (e.g.zidovudine)
• Protease inhibitors - block the viral protease
  enzyme
• Combined drug therapy
• Antimicrobial agents

15
AUTOIMMUNE DISEASES
16
Autoimmune disease

• Results from a failure of self-tolerance
• Immunological tolerance is specific
  unresponsiveness to an antigen
• All individuals are tolerant of their own (self)
  antigens

17
AUTOIMMUNE PATOLOGICAL RESPONSE- ETIOLOGY

• the diseases are chronic and usually irreversible
• incidence 5-7 of population, higher
  frequencies in women, increases with age
• factors contribute to autoimmunity
• - internal (HLA association, polymorphism
  of cytokine genes, defect in genes regulating
  apoptosis, polymorphism in genes for TCR a H
  immunoglobulin chains, association with
  immunodeficiency, hormonal factors)
• - external (infection, stress by activation
  of neuroendocrine axis and hormonal dysbalance,
  drug and ionization through modification of
  autoantigens)

18
CLINICAL CATEGORIES

• systemic
• - affect many organs and tissue
• organoleptic
• - affect predominantly one organ accompanied
  by affection of other organs (inflammatory bowel
  diseases, celiac disease, AI hepatitis, pulmonary
  fibrosis)
• organ specific
• - affect one organ or group of organs
  connected with development or function

19
SYSTEMIC AUTOIMMUNE DISEASES

• Systemic lupus erythematosus
• Rheumathoid arthritis
• Sjögrens syndrome
• Dermatopolymyositis
• Systemic sclerosis
• Mixed connective tissue disease
• Vasculitis

20
SYSTEMIC LUPUS ERYTHEMATOSUS

• chronic, inflammatory, multiorgan disorder
• autoantibodies react with nuclear material and
  attack cell function, immune complexes with
  dsDNA deposit in the tissue
• general symptoms include malaise, fever, weight
  loss
• multiple tissue are involved including the skin,
  mucosa, kidney, joints, brain and cardiovascular
  system
• characteristic features butterfly rash, renal
  involvement, CNS manifestation, pulmonary
  fibrosis

21
DIAGNOSTIC TESTS

• a elevated ESR (erythrocyte sedimentation rate),
  low CRP, trombocytopenia, leucopenia, hemolytic
  anemia, decreased levels of complement compounds
  (C4, C3), elevated serum Ig levels, immune
  complexes in serum

22
AUTOANTIBODIES

• Autoantibodies ANA, dsDNA (double-stranded), ENA
  (SS-A/Ro, SS-A/La), Sm, against histones,
  phospholipids

23
RHEUMATOID ARTHRITIS

• chronic, inflammatory disease with systemic
  involvement
• characterized by an inflammatory joint lesion in
  the synovial membrane, destruction of the
  cartilage and bone, results in the joint
  deformation
• clinical features arthritis, fever, fatigue,
  weakness, weight loss
• systemic features vasculitis, pericarditis,
  uveitis, nodules under skin, intersticial
  pulmonary fibrosis
• diagnostic tests elevated C- reactive protein
• and ESR, elevated serum gammaglobulin levels
• - autoantibodies against IgG rheumatoid
  factor
• (RF), a-CCP (cyclic citrulline peptid), ANA
  
• - X-rays of hands and legs- show a
  periarticular
• porosis, marginal erosion

24
SJÖGRENS SYNDROME

• chronic inflammatory disease affecting exocrine
  glands
• the primary targets are the lacrimal and salivary
  gland duct epithelium
• general features malaise, weakness, fever
• primary syndrome - features dry eyes and dry
  mouth, swollen salivary glands, dryness of the
  nose, larynx, bronchi and vaginal mucosa,
  involvement kidney, central and periferal nervous
  system, arthritis
• secondary syndrome is associated with others AI
  diseases (SLE, RA, sclerodermia, polymyositis,
  primary biliary cirhosis,AI thyroiditis)
• autoantibodies against ENA (SS-A, SS-B),
• ANA, RF
• The Schirmer test - measures the production
• of tears

25
Dermatopolymyositis

• a connective-tissue disease related to
  polymyositis (PM) that is characterized by
  inflammation of the muscles and the skin.

Gottron's sign is an erythematous, scaly eruption
occurring in symmetric fashion over the MCP and
interphalangeal joints
Heliotrope rash is a violaceous eruption on the
upper eyelids, often with swelling
26
Dermatopolymyositis

• Elevated creatine phosphokinase (CPK)
• muscle biopsy (a mixed B- and T-cell perivascular
  inflammatory infiltrate, perifascicular muscle
  fiber atrophy)
• EMG (electromyogram)
• autoantibodies - ENA (Jo-1)

27
Systemic sclerosis

• sclerosis in the skin or other organs
• Diffuse scleroderma (progressive systemic
  sclerosis) is the most severe form,
• involves skin, will generally cause internal
  organ damage (specifically the lungs and
  gastrointestinal tract)
• The limited form is much milder
• The limited form is often referred to as CREST
  syndrome (CREST is an acronym for the five main
  features Calcinosis, Raynaud's syndrome,
  Esophageal dysmotility, Sclerodactyly,
  Telangiectasia

28
Immunological findings

• ANA, ENA - anti-Scl-70 (fluorescence of
  nucleolus), anti-centromers

29
Mixed connective tissue disease

• combines features of polymyositis, systemic lupus
  erythematosus, scleroderma, and dermatomyositis
  (overlap syndrome)
• Symptoms joint pain/swelling, malaise, Raynaud
  phenomenon, muscle inflammation and sclerodactyly
  (thickening of the skin of the pads of the
  fingers)
• Distinguishing laboratory characteristics
• a positive, speckled anti-nuclear antibody
  (ANA) and anti-U1-RNP antibody (ENA)

30
Vasculitis

• characterized by inflammatory destruction
• of vessels leading to thrombosis and
  aneurysms
• proliferation of the intimal part of blood-vessel
  wall and fibrinoid necrosis
• affect mostly lung, kidneys, skin
• diagnostic tests elevated ESR, CRP,
  leucocytosis, biopsy of affected organ (necrosis,
  granulomas), angiography

31
Vasculitis

• p- ANCA (myeloperoxidase) positivity
  (Polyarteritis nodosa, Churg- Strauss,
  Microscopic polyarteritis nodosa)
• c- ANCA (serin proteinase) positive (Wegener
  
• granulomatosis, Churg- Strauss syndrome)

32
Classification

• Large vessel vasculitis (Takayasu arteritis,
  Giant cell (temporal) arteritis)
• Medium vessel vasculitis (Polyarteritis nodosa,
  Wegener's granulomatosis, Kawasaki disease)
• Small vessel vasculitis (Churg-Strauss arteritis,
  Microscopic polyarteritis, Henoch-Schönlein
  purpura)
• Symptoms fatigue, weakness, fever, arthralgias,
  abdominal pain, hypertension, renal
  insufficiency, and neurologic dysfunction

33
ORGANOLEPTIC AUTOIMMUNE DISEASES

• Ulcerative colitis
• Crohns disease
• Autoimmune hepatitis
• Primary biliary cirhosis
• Pulmonary fibrosis

34
Ulcerative colitis

• chronic inflammation of the large intestine
  mucosa and submucosa
• features diarrhea, bloody and mucus stools
• extraintestinal features (arthritis, uveitis)
• Autoantibodies pANCA, a- large intestine

35
Crohns disease

• the granulomatous inflammation of whole
  intestinal wall with ulceration and scarring that
  can result in abscess and fistula formation
• the inflammation of Crohn's disease the most
  commonly affects the terminal ileum, presents
  with diarrhea and is accompanied by
  extraintestinal features - iridocyclitis,
  uveitis, artritis, spondylitis
• antibodies against Saccharomyces cerevisiae
  (ASCA), a- pancreas

36
AUTOIMMUNE HEPATITIS

• type I association with autoantibodies against
  
• smooth muscles SMA, ANA, ANCA,
  SLA
• type II autoantibodies against microsomes LKM-1
  
• liver-kidney microsomes
• type III autoantibodies against SLA (solubile
  liver
• antigen)
• type IV overlap syndrome with PBC
• autoantibodies against
  mitochondries AMA

37
AUTOIMMUNE ENDOCRINOPATHY

• Hashimotos thyroiditis
• Graves-Basedow disease
• Diabetes mellitus I. type
• Addisons disease
• Autoimmune polyglandular syndrome

38
Hashimotos thyroiditis

• thyroid disease result to hypothyroidism on the
  base of lymphocytes and plasma cells infiltrate
• autoantibodies against thyroidal peroxidase
  (a-TPO) and/or against thyroglobulinu (a-TG)

39
Graves disease

• thyrotoxicosis from overproduction of thyroid
  hormone (patient exhibit fatigue, nervousness,
  increased sweating, palpitations, weight loss,
• exophtalmus)
• autoantibodies against thyrotropin receptor,
• autoantibodies cause thyroid cells
  proliferation

40
Diabetes mellitus (insulin- dependent)

• characterized by an inability to process sugars
  in the diet, due to a decrease in or total
  absence of insulin production
• results from immunologic destruction of the
  insuline- producing ß-cells of the islets of
  Langerhans in the pancreas
• autoantibodies against GAD (glutamic acid
  decarboxylase primary antigen), autoantibodies
  anti- islet cell, anti- insulin
• islets are infiltrated with B and T cells

41
AUTOIMMUNE NEUROPATHY

• Guillain-Barré syndrome (acute idiopathic
  polyneuritis)
• Myasthenia gravis
• Multiple sclerosis

42
Multiple sclerosis

• chronic demyelinizing disease with abnormal
  reaction T cells to myeline protein on the base
  of mimicry between a virus and myeline protein
• features weakness, ataxia, impaired vision,
  urinary bladder dysfunction, paresthesias, mental
  abberations
• autoantibodies against MOG (myelin-oligodendrocyt
  e glycoprotein)
• Magnetic resonance imaging of the brain and spine
  shows areas of demyelination
• The cerebrospinal fluid is tested for oligoclonal
  bands, can provide evidence of chronic
  inflammation of the central nervous system

43
AUTOIMMUNE CYTOPENIA

• AI hemolytic disease- autoantibodies against
  membrane erythrocyte antigens
• AI trombocytopenia - autoantibodies against
• trombocyte antigens (GPIIb/IIIa)
• AI neutropenia - autoantibodies against
• membrane neutrofil antigens

44
Treatment of autoimmune diseases

• Systemic AI non-specific immunosuppression
  glucocorticoids
• cytostatics
• alkylating agents -
• cyclophosphamide
• purine analogs - azathioprine,
• mycophenolate,
• antimetabolites - metotrexate
• antibiotics - cyclosporin A,
• tacrolimus
• monoclonal antibodies

• Organ specific AI -
• non-specific immunosuppression
• Endocrinopathies -
• Substitution of lacking product of endocrinal
  gland destroyed by AI process
• insulin, thyroid gland
• hormones